KYMR SEC Filing News — Kymera Therapeutics, Inc.

Latest SEC filings for Kymera Therapeutics, Inc. (KYMR) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-01.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune disease…
Sector: Healthcare Industry: Biotechnology Market Cap: $8.9B CIK: 1815442
20
Total Filings
0
Bullish Classifications
8
Bearish Classifications
9
Insider Transactions
2
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for KYMR currently lean bearish. Of the 20 filing records displayed, 8 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
KYMR Filing Activity Snapshot 2026-06-29 — 2026-10-01
Insider Transactions (Form 4)
0 buys vs 8 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$56.46M
Booth Bruce (Director) · 2026-06-30
513,245 shares · Form 4
Form 144 Notices
8
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for Kymera Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 8 open-market sale and 1 compensation award. 8 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×8
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×1
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Form 4 Open-market sale Insider Selling 2026-10-01

KYMR insider Mainolfi Nello (Director, Chief Executive Officer) sold 30,000 shares (~$3.41M)

Mainolfi Nello, listed as Director, Chief Executive Officer at Kymera Therapeutics, Inc., reported an open-market sale of 30,000 KYMR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 30,000 $2.08 $62.4K
S Open-market sale 3,525 $111.44 $392.8K
S Open-market sale 5,506 $112.42 $619.0K
S Open-market sale 4,876 $113.24 $552.2K
S Open-market sale 7,601 $114.43 $869.8K
S Open-market sale 8,230 $115.40 $949.7K
S Open-market sale 262 $116.12 $30.4K
M Option exercise derivative · Stock Option (Right to Buy) 30,000 — —
Filing: Form 4 (Insider Transaction) Insider: Mainolfi Nello (Director, Chief Executive Officer) Shares: 30,000 Est. Value: $3.41M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-04

KYMR insider Adams Brian (Chief Legal Officer) sold 6,371 shares (~$744.3K)

Adams Brian, listed as Chief Legal Officer at Kymera Therapeutics, Inc., reported an open-market sale of 6,371 KYMR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,209 $115.55 $139.7K
S Open-market sale 3,025 $116.81 $353.4K
S Open-market sale 2,137 $117.57 $251.2K
Filing: Form 4 (Insider Transaction) Insider: Adams Brian (Chief Legal Officer) Shares: 6,371 Est. Value: $744.3K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-27

KYMR insider Form 4 filed for equity award, exercise, or tax withholding

Rooney Terence (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 38,000 — —
A Compensation award derivative · Stock Option (Right to Buy) 76,000 — —
Filing: Form 4 (Insider Transaction) Insider: Rooney Terence (Chief Medical Officer) Shares: 38,000
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-07

KYMR insider Mainolfi Nello (Director, Chief Executive Officer) sold 50,000 shares (~$5.95M)

Mainolfi Nello, listed as Director, Chief Executive Officer at Kymera Therapeutics, Inc., reported an open-market sale of 50,000 KYMR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 50,000 $2.08 $104.0K
S Open-market sale 50,000 $119.00 $5.95M
M Option exercise derivative · Stock Option (Right to Buy) 45,559 — —
M Option exercise derivative · Stock Option (Right to Buy) 4,441 — —
Filing: Form 4 (Insider Transaction) Insider: Mainolfi Nello (Director, Chief Executive Officer) Shares: 50,000 Est. Value: $5.95M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-02

KYMR insider Jacobs Bruce N. (Chief Financial Officer) sold 77,109 shares (~$8.86M)

Jacobs Bruce N., listed as Chief Financial Officer at Kymera Therapeutics, Inc., reported an open-market sale of 77,109 KYMR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 61,378 $5.33 $327.1K
S Open-market sale 1,500 $110.54 $165.8K
S Open-market sale 1,700 $111.57 $189.7K
S Open-market sale 1,100 $112.79 $124.1K
S Open-market sale 4,110 $114.19 $469.3K
S Open-market sale 51,375 $114.77 $5.90M
S Open-market sale 7,971 $115.82 $923.2K
S Open-market sale 6,153 $116.99 $719.9K
S Open-market sale 3,200 $117.70 $376.6K
M Option exercise derivative · Stock Option (Right to Buy) 61,378 — —
Filing: Form 4 (Insider Transaction) Insider: Jacobs Bruce N. (Chief Financial Officer) Shares: 77,109 Est. Value: $8.86M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-02

KYMR insider Goodman Noah (Chief Business Officer) sold 3,389 shares (~$387.3K)

Goodman Noah, listed as Chief Business Officer at Kymera Therapeutics, Inc., reported an open-market sale of 3,389 KYMR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 3,389 $114.29 $387.3K
Filing: Form 4 (Insider Transaction) Insider: Goodman Noah (Chief Business Officer) Shares: 3,389 Est. Value: $387.3K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-02

KYMR insider Mainolfi Nello (Director, Chief Executive Officer) sold 80,000 shares (~$9.22M)

Mainolfi Nello, listed as Director, Chief Executive Officer at Kymera Therapeutics, Inc., reported an open-market sale of 80,000 KYMR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 80,000 $2.08 $166.4K
S Open-market sale 1,883 $112.80 $212.4K
S Open-market sale 6,626 $113.98 $755.2K
S Open-market sale 24,105 $114.96 $2.77M
S Open-market sale 44,050 $115.69 $5.10M
S Open-market sale 3,336 $116.56 $388.8K
M Option exercise derivative · Stock Option (Right to Buy) 80,000 — —
Filing: Form 4 (Insider Transaction) Insider: Mainolfi Nello (Director, Chief Executive Officer) Shares: 80,000 Est. Value: $9.22M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-30

KYMR insider Booth Bruce (Director) sold 31,283 shares (~$3.42M)

Booth Bruce, listed as Director at Kymera Therapeutics, Inc., reported an open-market sale of 31,283 KYMR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 10,658 $108.28 $1.15M
S Open-market sale 7,833 $109.75 $859.7K
S Open-market sale 7,602 $110.67 $841.3K
S Open-market sale 907 $111.20 $100.9K
S Open-market sale 1,688 $108.28 $182.8K
S Open-market sale 1,239 $109.75 $136.0K
S Open-market sale 1,199 $110.67 $132.7K
S Open-market sale 157 $111.20 $17.5K
Filing: Form 4 (Insider Transaction) Insider: Booth Bruce (Director) Shares: 31,283 Est. Value: $3.42M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-30

KYMR insider Booth Bruce (Director) sold 513,245 shares (~$56.46M)

Booth Bruce, listed as Director at Kymera Therapeutics, Inc., reported an open-market sale of 513,245 KYMR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 28,296 $107.57 $3.04M
S Open-market sale 231,007 $108.14 $24.98M
S Open-market sale 32,624 $109.79 $3.58M
S Open-market sale 11,277 $110.49 $1.25M
S Open-market sale 10,366 $111.51 $1.16M
S Open-market sale 555 $112.49 $62.4K
S Open-market sale 14,913 $113.97 $1.70M
S Open-market sale 27,951 $114.94 $3.21M
S Open-market sale 6,821 $115.69 $789.1K
S Open-market sale 12,181 $117.09 $1.43M
S Open-market sale 22,046 $117.85 $2.60M
S Open-market sale 12,390 $118.66 $1.47M
S Open-market sale 3,958 $107.57 $425.8K
S Open-market sale 32,402 $108.14 $3.50M
S Open-market sale 4,562 $109.79 $500.9K
S Open-market sale 1,579 $110.49 $174.5K
S Open-market sale 1,442 $111.51 $160.8K
S Open-market sale 78 $112.49 $8.8K
S Open-market sale 2,083 $113.97 $237.4K
S Open-market sale 3,896 $114.94 $447.8K
S Open-market sale 952 $115.69 $110.1K
S Open-market sale 1,701 $117.09 $199.2K
S Open-market sale 3,069 $117.85 $361.7K
S Open-market sale 1,729 $118.66 $205.2K
S Open-market sale 5,471 $105.78 $578.7K
S Open-market sale 14,613 $106.63 $1.56M
S Open-market sale 19,093 $107.76 $2.06M
S Open-market sale 848 $105.78 $89.7K
S Open-market sale 2,318 $106.63 $247.2K
S Open-market sale 3,024 $107.76 $325.9K
Filing: Form 4 (Insider Transaction) Insider: Booth Bruce (Director) Shares: 513,245 Est. Value: $56.46M
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 8 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Kymera Therapeutics, Inc. has 8 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-01

KYMR Form 144 filed for proposed insider sale by Mainolfi Nello (30,000 shares) ~$3.35M

Mainolfi Nello filed a Form 144 with the SEC indicating intent to sell KYMR (Kymera Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Mainolfi Nello Shares: 30,000 Est. Value: $3.35M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-04

KYMR Form 144 filed for proposed insider sale

An insider at Kymera Therapeutics, Inc. filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.

Filing: Form 144 (Proposed Sale Notice)
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-02

KYMR Form 144 filed for proposed insider sale

An insider at Kymera Therapeutics, Inc. filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.

Filing: Form 144 (Proposed Sale Notice)
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-07

KYMR Form 144 filed for proposed insider sale

An insider at Kymera Therapeutics, Inc. filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.

Filing: Form 144 (Proposed Sale Notice)
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-02

KYMR Form 144 filed for proposed insider sale

An insider at Kymera Therapeutics, Inc. filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.

Filing: Form 144 (Proposed Sale Notice)
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-01

KYMR Form 144 filed for proposed insider sale

An insider at Kymera Therapeutics, Inc. filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.

Filing: Form 144 (Proposed Sale Notice)
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-30

KYMR Form 144 filed for proposed insider sale

An insider at Kymera Therapeutics, Inc. filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.

Filing: Form 144 (Proposed Sale Notice)
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-29

KYMR Form 144 filed for proposed insider sale

An insider at Kymera Therapeutics, Inc. filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.

Filing: Form 144 (Proposed Sale Notice)
View on SEC EDGAR → Open Filing Document →
Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Kymera Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-05

KYMR filed 8-K — material company event

Kymera Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-27

KYMR filed 8-K — material company event

Kymera Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Read the SEC filing for the full details.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Kymera Therapeutics, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-05

KYMR filed Quarterly Report (10-Q)

Kymera Therapeutics, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Kymera Therapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on KYMR. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — KYMR SEC Filings

More Tools for KYMR

KYMR Full Stock Analysis KYMR Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper KYMR analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the KYMR stock analysis page.

KYMR Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer